James Zidar
Interventional Cardiology · Raleigh, NCNPI 1205910189
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (44.4%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. Medtronic accounts for 73.8% of it on its own, with 26 other manufacturers making up the rest.
Across 164 payments — averaging $348.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$42K
- Abbott$6K
- Cordis US CORP.$3K
- Contego Medical, Inc$3K
- Abiomed$1K
- Boston Scientific$482
- plus $2K from 21 others
Across 134 payments — averaging $8099.91 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Contego Medical, Inc$734K
- Janssen Research & Development, LLC$103K
- Shockwave Medical, Inc$89K
- Abbott$75K
- CSL Behring$66K
- Boston Scientific$19K
What the payments were for
- Consulting fees$25,39044%
- Speaking & faculty fees$16,86029%
- Grants$1000%
- Travel & lodging$7,03312%
- Food & beverage$7,81914%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 78 | $42,233 |
| Abbott | 24 | $5,636 |
| Cordis US CORP. | 4 | $2,940 |
| Contego Medical, Inc | 2 | $2,916 |
| Abiomed | 10 | $1,261 |
| Boston Scientific | 5 | $482 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 12 | $398 |
| Silk Road Medical, Inc. | 1 | $300 |
| Ablative Solutions, Inc. | 4 | $294 |
| Biotronik Inc. | 1 | $130 |
| Irhythm Technologies, Inc. | 3 | $86 |
| Bolton Medical Inc | 1 | $71 |
| Pfizer | 1 | $67 |
| Surmodics, Inc. | 1 | $57 |
| AstraZeneca | 3 | $53 |
| Angiodynamics, Inc. | 1 | $42 |
| Terumo Medical Corporation | 2 | $35 |
| Cardinal Health 200 LLC | 1 | $30 |
| Johnson & Johnson | 2 | $29 |
| CSL Behring | 1 | $24 |
| Actelion Pharmaceuticals US, Inc. | 1 | $23 |
| Amgen | 1 | $21 |
| Alnylam Pharmaceuticals Inc. | 1 | $17 |
| Janssen Scientific Affairs, LLC | 1 | $17 |
| Gilead | 1 | $16 |
| Heartflow, Inc. | 1 | $13 |
| Sensible Medical Innovations Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Resolute$16,424
- Xience V coronary stent system$4,750
- Impella$1,045
- RESOLUTE ONYX$1,032
- MYNX CONTROL$1,013
- ONYX FRONTIER$638
- MO.MA ULTRA$603
- ENROUTE Transcarotid Stent$300
- ENROUTE Transcarotid Neuroprotection System$300
- SYMPLICITY G3$263
- AVVIGO Guidance System$262
- OPTIS$198
- ClosureFast$163
- GENERAL - STRUCTURAL HEART$134
- Xience Sierra Coronary Stent System$132
- Orsiro Mission$130
- LifeVest$111
- Abre$110
How this compares
$57,202 in reported general payments places this provider in the 85th percentile of 180 interventional cardiology providers in North Carolina.
See all interventional cardiology providers in North Carolina →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 517 | $493,930 |
| XareltoRivaroxaban | 110 | $89,137 |
| Repatha SureclickEvolocumab | 62 | $61,756 |
| BrilintaTicagrelor | 19 | $19,992 |
| EntrestoSacubitril/Valsartan | 18 | $15,910 |
| Metoprolol Succinate | 804 | $9,907 |
| Losartan Potassium | 512 | $5,471 |
| ClopidogrelClopidogrel Bisulfate | 450 | $5,074 |
| Rosuvastatin Calcium | 431 | $4,804 |
| Flecainide Acetate | 134 | $4,698 |
| Atorvastatin Calcium | 376 | $3,959 |
| Dofetilide | 12 | $3,350 |
| Ranolazine ErRanolazine | 49 | $3,251 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 82 | $2,881 |
| Prasugrel Hcl | 42 | $2,325 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $67 | $493,930517 claims |
| Johnson & JohnsonXarelto | $29 | $89,137110 claims |
| AstraZenecaBrilinta | $53 | $19,99219 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 180 interventional cardiology providers in North Carolina.
Other interventional cardiology in Raleigh
- Ravish SacharRaleigh$1.6M
- Robert JobeRaleigh$191K
- Willis WuRaleigh$56K
- Islam OthmanRaleigh$50K
- Andrew SampsonRaleigh$48K
- Dwijesh PatelRaleigh$40K
- Siva KethaRaleigh$19K
- Mohit PasiRaleigh$16K
- George AdamsGarner$4.1M
- Paul MahoneyGreenville$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.